Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints

Lancet

Volumn 354, Issue 9194, 1999, Pages 1940-1947

  Levi, Marcel ^a   Cromheecke, Manon E ^a   Jonge, Evert De ^a   Prins, Martin H ^a   De Mol, Bas J M ^a   Briët, Ernest ^a   Büller, Harry R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; DESMOPRESSIN; LYSINE DERIVATIVE; TRANEXAMIC ACID;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; HEART INFARCTION; HEART SURGERY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SURGICAL MORTALITY; TREATMENT OUTCOME;

EID: 0033524140     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)01264-7     Document Type: Article

References (105)

1. Dacey L.J., Munoz J.J., Baribeau Y.R.et al. Rexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg. 133:1998;442-447.
2. Unsworth-White M.J., Herriot A., Valencia O. Resternotomy for bleeding after cardiac operation: a marker for increase morbidity and mortality. Ann Thorac Surg. 59:1995;664-667.
3. Harker L.A. Bleeding after cardiopulmonary surgery. N. Engl J. Med. 314:1986;1446-1448.
4. Mannucci P.M. Hemostatic drugs. N. Engl, J. Med. 339:1998;245-253.
5. Fremes S.E., Wong B.I., Lee E.et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg. 58:1994;1580-1588.
6. Laupacis A., Ferguson D. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Drugs to minimise perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg. 85:1997;1258-1267.
7. Gschossmann J., Pracki P., Struck E. Efficacy of aprotinin in different doses and autologous blood transfusions in cardiac surgery. Cardiovasc Surg. 2:1994;716-719.
8. Carrel T., Bauer E., Laske A., von Segesser L., Turina M. Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass. Lancet. 337:1991;673.
9. 2-plasmin inhibitor complexes and postoperative blood loss. Eur J Cardiothor Surg. 9:1995;143-145.
10. Kawasuji M., Ueyama K., Sakakibara N.et al. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann Thorac Surg. 55:1993;1205-1229.
11. VanderSalm T.J., Ansell J.E., Okike O.N.et al. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg. 112:1996;1125-1127.
12. Andersson T.L.G., Solem J.O., Tengborn L., Vinge E. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation. 81:1990;872-878.
13. Frankville D.D., Harper G.B., Lake C.L., Johns R.A. Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass. Anesthesiol. 74:1991;988-996.
14. Brown M.R., Swygert T.H., Whitten C.W., Hebeler R. Desmopressin acetate following cardiopulmonary bypass: evaluation of coagulation parameters. J Cardiothor Anesth. 3:1989;726-729.
15. Eberle B., Mayer E., Hafner G.et al. High-dose epsilon-aminocaproic acid versus aprotinin: antifibrinolytic efficacy in first time coronary operations. Ann Thorac Surg. 65:1998;667-673.
16. Gherli T., Porcu A., Padua G.et al. Riduzione del sanguinamento negli interventi in circolazione extracorporea mediante l'uso di alte dosi di aprotinina. Minerva Cardiol. 40:1992;121-126.
17. Dietrich W., Barankay A., Dilthey G.et al. Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application: clinical experience in 152 cardiac surgical patients. Thorac Cardiovasc Surgeon. 37:1989;92-98.
18. Blauhut B., Cross C., Necek S., Doran J.E., Späth P., Lunsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 101:1991;958-967.
19. Nakashima A., Matsuzaki F., Fukumura F.et al. Tranexamic acid reduces blood loss after cardiopulmonary bypass. ASAIO J. 39:1993;119-185.
20. Lazenby W.D., Russo I., Zadeh B.J.et al. Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis. Circulation. 82:1990;413-419. (suppl).
21. Chuang H.I., Horng Y.J., Li Y.et al. Clinical assessment of desmopressin to reduce loss in patients after cardiopulmonary bypass. Acta Anaesthesiol Sin. 31:1993;35-42.
22. Lambert W., Brisebois F.J., Wharton T.J., Carrier R.C., Boyle D., Rowe B.H. The effectiveness of low dose tranexamic acid in primary cardiac surgery. Can J Anaesth. 45:1998;571-574.
23. Osaka M., Fujuda I., Ohuchi H. Aprotinin and recombinant human erythropoietin reduce the need for homologous blood transfusion in cardiac surgery. Nippon Kyobu Geka Gakkai Zasshi. 46:1998;846-853.
24. Boldt J., Knothe C., Zickmann B., Wege N., Dapper F., Hempelmann G. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. J. Thorac Cardiovasc Surg. 105:1993;705-711.
25. Zonis Z., Seear M., Reichert C., Sett S., Allen C. The effect of preoperative transexamic acid on blood loss after cardiac operations in children. J. Thorac Cardiovasc Surge. 111:1996;982-987.
26. Seear M.D., Wadsworth L.D., Rogers P.C., Sheps S., Ashmore P.G. The effect of desmopressin acetate (DDAVP) on postoperative blood loss after cardiac operations in children. J Thorac Cardiovasc Surg. 98:1989;217-229.
27. Reynolds L.M., Nicolson S.C., Jobes D.R.et al. Desmopressin does not decrease bleeding after cardiac operation in young children. J Thorac Cardiovasc Surg. 106:1993;954-958.
28. Miller B.E., Tosone S.R., Tam V.K.et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thor Surg. 66:1998;535-540.
29. Royston D., Bidstrup B.P., Taylor K.M., Sapsford R.N. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. ii:1987;1289-1291.
30. Cosgrove D.M., Heric B., Lytle B.W.et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg. 54:1992;1031-1038.
31. Speekenbrink R.G.H., Vonk A.B.A., Wildevuur C.R.H., Eijsman L. Hemostatic efficiency of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg. 59:1995;438-442.
32. Swart M.J., Gordon P.C., Hayse-Gregson P.B.et al. High-dose aprotinin in cardiac surgery: a prospective, randomised study. Anaesth Intensive Care. 22:1994;529-533.
33. Dietrich W., Spannagl M., Jochum M.et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology. 73:1990;1119-1126.
34. Dietrich W., Dilthey G., Spannagl M., Jochum M., Braun S.L., Richter J.A. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin pretreated patients undergoing open-heart surgery. Anesthesiology. 83:1995;679-689.
35. Liu B., Belboul A., Radberg G.et al. Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg. 27:1993;149-155.
36. Bidstrup B.P., Royston D., Sapsford R.N., Taylor K.M. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 97:1989;364-372.
37. Alvarez J.M., Quiney N.F., McMillan D.et al. The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. J Cardiothorac Vasc Anesth. 9:1995;29-33.
38. Speekenbrink R.G.H., Wildevuur C.R.H., Sturk A., Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J. Thorac Cardiovasc Surg. 112:1996;523-530.
39. Vedrinne C., Girard C., Jegqden O.et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth. 6:1992;319-323.
40. Levy J.H., Pifarre R., Schaff H.V.et al. A multicentre, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion inpatients undergoing repeat coronary artery bypass grafting. Circulation. 92:1995;2236-2244.
41. Havel M., Grabenwöger F., Schneider J.et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg. 107:1994;807-810.
42. Murkin J.M., Lux J., Shannon N.A.et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 107:1994;554-561.
43. Lemmer J.H., Stanford W., Bonney S.L.et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg. 107:1994;543-553.
44. Green D., Sanders J., Eiken M.et al. Recombinant aprotinin in coronary artery bypass graft operations. J Thorac Cardiovasc Surg. 110:1995;963-970.
45. Havel M., Teufelsbauer H., Knöbl P.et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg. 101:1991;968-972.
46. Bailey C.R., Kelleher A.A., Wielogorski A.K. Randomised placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery. Br J Surg. 81:1994;969-973.
47. Hardy J.F., Desroches J., Belisle S., Perrault J., Carrier M., Robitalle D. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth. 40:1993;625-631.
48. Lemmer J.H. Jr., Dilling E.W., Morton J.R.et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg. 62:1996;1659-1668.
49. Deleuze O., Losance D.Y., Feliz A.et al. Réduction des pertes sanguines per et postopératoires par l'aprotinine (Trasylol) au cours de la circulation extracorporelle. Arch Mal Coeur. 84:1991;1797-1802.
50. Bailey C.R., Wielogorski A.K. Randomised placebo-controlled double blind study of two low dose aprotinin regimens in cardiac surgery. Br Heart J. 71:1994;349-353.
51. Ray M.J., Marsh N.A., Just S.J.E., Perrin E.J., O'Brien M.F., Hawson G.A.T. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass. Ann Thorac Surg. 63:1997;57-63.
52. Orchard M.A., Goodchild C.S., Prentice C.R.M.et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol. 85:1993;533-541.
53. Bidstrup B.P., Underwood S.R., Sapsford R.N., Streets E. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg. 105:1993;147-153.
54. Laub G.W., Riebman J.B., Chen C.et al. The impact of aprotinin on coronary artery bypass graft patency. Chest. 106:1994;1370-1375.
55. Rodrigus I.E., Vermeyen K.M., de Hert S.G., Amsel B.J., Walter P.J. Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study. Perfusion. 11:1996;313-338.
56. Mohr R., Goor D.A., Lusky A., Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction: a scanning electron microscope study. Circulation. 86:1992;405-409. (suppl).
57. Baele P.L., Ruiz-Gomez J., Londot C., Sauvage M., van Dyck M.J., Robert A. Systematic use of aprotinin in cardiac surgery: influence of total homolgous exposure and hospital cost. Acta Anaesth Belg. 43:1992;103-112.
58. Menichetti A., Tritapepe L., Ruvolo G.et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg. 37:1996;401-407.
59. Kalanhgos A., Tayyareci G., Prêtre R., Di Dio P., Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg. 8:1994;651-656.
60. Hardy J.F., Bélisle S., Couturier A., Robitaille D. Randomized, placebo-controlled, double-blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations. J Card Surg. 12:1997;15-22.
61. Corbeau J.J., Monrigal J.P., Jacob J.P.et al. Comparaison des effets de l'aprotinine at de l'acide tranexamique sur le saignement en chirurgie cardiaque. Ann Fr Anesth Réanim. 14:1995;154-161.
62. Penta de Peppo A., Pierri M.D., Scafuru A.et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery: prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J. 22:1995;231-236.
63. Landymore R.W., Murphy J.T., Lummis H., Carter C. The use of low-dose aprotinin, ε-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations. Eur J Cardiothorac Surg. 11:1997;798-800.
64. Harder M.P., Eijsman L., Roozendaal K.J., van Oeveren W., Wildevuur C.R.H. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg. 51:1991;936-941.
65. Pugh S.C., Wielogorski A.K. A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J. Cardiothorac Vasc Anesth. 9:1995;240-244.
66. Rocha E., Hidalgo F., Llorens R., Melero J.M., Arroyo J.L., Paramo J.A. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation. 90:1994;921-927.
67. Rossi M., Storti S., Martinelli L.et al. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effect on the hemostatic system. J Cardiothorac Vasc Anesth. 11:1997;835-839.
68. Jamieson W.R.E., Dryden P.J., O'Connor J.P., Sadeghi H., Ansley D.M., Merrick P.M. Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery. Circulation. 96:1997;96-101. (suppl).
69. Ciçek S., Demirkiliç U., Kuralay E., Özal E., Tatar H. Postoperative aprotinin: effect on blood loss and transfusion requirements in cardiac operations. Ann Thorac Surg. 61:1996;1372-1376.
70. Minohara S., Asada K., Kondo K.et al. Effect of aprotinin on bleeding and graft patency after coronary artery bypass grafting. Nippon Kyobu Geka Gakkai Zasshi. 45:1997;821-824.
71. Carrera A., Martinez M.V., Garcia-Guiral M., Herrero E., Peral A., Planas A. Use of high doses of aprotinin in cardiac surgery. Rev Espan Anestesiol Reanim. 41:1994;13-19.
72. Klein M., Keith P.R., Dauben H.P.et al. Aprotinin counterbalances an increased risk of perioperative hemorrhage in CABG patients pre-treated with aspirin. Eur J Cardiothorac Surg. 14:1998;360-366.
73. Lass M., Simic O., Ostermeyer J. Re-graft patency and clinical efficacy of a protinin in elective bypass surgery. Cardiovasc Surg. 5:1997;604-607.
74. Alderman E.L., Levy J.H., Rich J.B.et al. The IMAGE investigators. Analyses of coronary graft patency after aprotinin use: results from the International Multicentre Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 116:1998;716-730.
75. Horrow J.C., van Riper D.F., Strong M.D., Brodsky I., Parmet J.L. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation. 84:1991;2063-2070.
76. Shorre-Lesserson L., Reich D.L., Vela-Cantos F., Ammar T., Ergin M.A. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Anaesth Analg. 83:1996;18-26.
77. Horrow J.C., Hlavacek J., Strong M.D.et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg. 99:1990;70-74.
78. Vandersalm T.J., Kaur S., Lancey R.A. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J. Thorac Cardiovasc Surg. 112:1996;1098-1107.
79. Delrossi A.J., Ceraianu A.C., Botros S., Lemole G.M., Moore R. Prophylactic treatment of postperfusion bleeding using EACA. Chest. 96:1989;27-30.
80. Daily P.O., Lamphere J.A., Demitsky W.P., Adamson R.M., Dans N.F. Effect of prophylactic epilson-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: a randomized, prospective, double-blind study. J Thorac Cardiovasc Surg. 108:1994;99-108.
81. Coffey A., Pittmam J., Halbrook H., Fehrenbacher J., Beckman D., Hormuth D. The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial. Am Surgeon. 61:1995;566-568.
82. Brown R.S., Thwaites B.K., Mongan P.D. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, placebo-controlled trial. Anesth Analg. 85:1997;963-970.
83. Dryden P.J., O'Connor P., Jamieson W.R.E.et al. Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery. Can J Anaesth. 44:1997;934-941.
84. Hardy J.F., Bélisle S., Dupont C.et al. Prophylactic tranexamic acid and ε-aminocaproic acid for primary myocardial revascularization. Ann Thorac Surg. 65:1998;371-376.
85. Pinosky M.L., Kennedy D.J., Fishman R.L.et al. Tranexamic acid reduces bleeding after cardiopulmonary bypass when compared to epsilon aminocaproic acid and placebo. J Card Surg. 12:1997;330-338.
86. de Prost D., Barbier-Boehm G., Hazebroucq J.et al. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass. Thromb Haemost. 68:1992;106-110.
87. Hackmann T., Gascoyne R.D., Naiman S.C.et al. A trial of desmopressin (1-deamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med. 321:1989;1437-1443.
88. Salzman E.W., Weinstein M.K., Weintraub R.M. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. N. Engl J. Med. 314:1986;1402-1406.
89. Reich D.L., Hammerschlag B.C., Rand J.H.et al. Desmopressin acetate is a mild vasodilatator that does not reduce blood loss in uncomplicated cardiac surgical procedures. J Cardiothorac Vasc Anesth. 5:1991;142-145.
90. Marquez J., Koehler S., Strelec S.R.et al. Repeated dose administration of desmopressin acetate in uncomplicated cardiac surgery: a prospective, blinded, randomized study. J Cardiothorac Vasc Anesth. 6:1992;674-676.
91. Dilthey G., Dietrich W., Spannagl M., Richter J.A. Influence of desmopressin acetate on homologous blood requirements in cardiac surgery patients pretreated with aspirin. J. Cardiothorac Vasc Anesth. 7:1993;425-430.
92. Ansell J., Klassen V., Lew R.et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. J Thorac Cardiovasc Surg. 104:1992;117-123.
93. Gratz I., Koehler J., Olsen D.et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg. 104:1992;1417-1422.
94. Rocha E., Llorens R., Paramo J.A., Arcas R., Cuesta B., Trenor A.M. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation. 77:1988;1319-1323.
95. Mongan P.D., Hosking M.P. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery: a controlled clinical trial with thrombelastographic risk stratification. Anesthesiology. 77:1992;38-46.
96. Hedderich G.S., Petsikass D.J., Cooper B.A.et al. Desmopressin acetate in uncomplicated coronary artery bypass surgery: a prospective randomized clinical trial. Can J Surg. 33:1990;33-37.
97. Temeck B.K., Bachenheimer L.C., Katz N.M., Coughlin S.S., Wallace R.B. Desmopressin acetate in cardiac surgery: a double-blind randomized study. South Med J. 87:1994;611-615.
98. Sheridan D.P., Card R.T., Pinilla J.C.et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg. 37:1994;33-37.
99. Spyt T.J., Weerasena N.A., Brain W.H. The effects of desmopressin acetate (DDAVP) on haemostasis and blood loss in routine coronary artery bypass surgery: a randomized, double-blind trial. Perfusion. 5:1990;57-61. (suppl).
100. Bennett-Guerrero E., Sorohan J., Gurevich M.L.et al. Cost-benefit and efficacy of aprotinin compared with ε-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded trial. Anesthesiology. 87:1997;1373-1380.
101. Mongan P.D., Brown R.S., Thwaites B.K. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularisation. Anesth Analg. 87:1998;258-265.
102. Cattaneo M., Harris A.S., Strömberg U., Mannucci P.M. The effect of desmopressin on reducing blood loss in cardiac surgery: a meta-analysis of double-blind placebo-controlled trials. Thromb Haemost. 74:1995;1064-1070.
103. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth. 6:1992;76-100.
104. van der Meer J., Hillege H.L., Ascoop C.A.et al. Aprotinin in aortocoronary bypass surgery: increased risk of vein graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thromb Haemost. 75:1996;1-3.
105. Smith P.K., Muhlbaier L.H. Aprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg. 62:1996;1575-1577.